Enhanced efficacy of anticonvulsants when combined with levetiracetam in soman-exposed rats

NeuroToxicology

Volumn 32, Issue 6, 2011, Pages 923-930

  Myhrer, Trond ^a   Enger, Siri ^a   Jonassen, Morten ^a,b   Aas, Pål ^a  

^a NORWEGIAN DEFENCE RESEARCH ESTABLISHMENT FFI   (Norway)

^b Norwegian Defence Medical Services   (Norway)

Author keywords

Caramiphen; Ketamine; Levetiracetam; Muscimol; NBQX; Procyclidine; Seizures; Soman intoxication; Treatment

Indexed keywords

1 (4 CARBAMOYLPYRIDINIO) 1' (2 HYDROXYIMINOMETHYLPYRIDINIO)DIMETHYL ETHER; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; CARAMIPHEN; ETIRACETAM; KETAMINE; MECAMYLAMINE; MUSCIMOL; PROCYCLIDINE; PYRIDOSTIGMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HISTOPATHOLOGY; LATENT PERIOD; MALE; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; SURVIVAL RATE; TREATMENT RESPONSE;

ANIMALS; ANTICONVULSANTS; ANTIDOTES; CHEMICAL WARFARE AGENTS; CHOLINESTERASE INHIBITORS; CHOLINESTERASE REACTIVATORS; CYCLOPENTANES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; LETHAL DOSE 50; MALE; MOTOR ACTIVITY; MUSCIMOL; NICOTINIC ANTAGONISTS; PIRACETAM; PROCYCLIDINE; QUINOXALINES; RATS; RATS, WISTAR; REACTION TIME; SEIZURES; SOMAN; TIME FACTORS;

RATTUS;

EID: 80055094376     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2011.04.008     Document Type: Article

References (47)

1. Aas P. Future considerations for the medical management of nerve agent intoxication. Prehosp Disast Med 2003, 18:208-216.
2. Amourette C., Lamproglou I., Barbier L., Fauquette W., Zoppe A., Viret R., Diserbo M. Gulf War illness: effects of repeated stress and pyridostigmine treatment in blood-brain barrier permeability and cholinesterase activity in rat brain. Behav Brain Res 2009, 203:207-214.
3. Annetta M.G., Iemma D., Garisto C., Tafani C., Proietti R. Ketamine: new indications for an old drug. Curr Drug Targets 2005, 6:789-794.
4. Carpentier P., Foquin A., Kamenka J.-M., Rondouin G., Lerner-Natoli M., de Groot D.M.G., Lallement G. Effects of thienylphencyclidine (TCP) on seizure activity and brain damage produced by soman in guinea-pigs: ECoG correlates of neurotoxicity. Neurotoxicology 2001, 22:13-28.
5. Cassel G.E., Fosbraey P. Measurement of the oxime HI-6 after peripheral administration in tandem with neurotransmitter levels in striatal dialysates: effects of soman intoxication. J Pharmacol Toxicol Methods 1996, 35:159-166.
6. Dorandeu F., Carpentier P., Baubichon D., Four E., Bernabé D., Burckhart M.-F., Lallement G. Efficacy of ketamine-atropine combination in the delayed treatment of soman-induced status epilepticus. Brain Res 2005, 1051:164-175.
7. Gale K. Progression and generalization of seizure discharge: anatomical and neurochemical substrates. Epilepsia 1988, 29(Suppl. 2):S15-S34.
8. Gao Z.G., Liu B.Y., Cui W.Y., Li L.J., Fan Q.H., Liu C.G. Anti-nicotinic properties of anticholinergic antiparkinson drugs. J Pharm Pharmacol 1998, 50:1299-1305.
9. Goldman H., Berman R.F., Hazlett J., Murphy S. Cerebrovascular responses to soman: time and dose dependent effects. Neurotoxicology 1993, 14:469-484.
10. Harris L.W., McDonough J.H., Stitcher D.L., Lennox W.J. Protection against both lethal and behavioral effects of soman. Drug Chem Toxicol 1984, 7:605-624.
11. Kaminski R.M., Matagne A., Patsalos P.N., Klitgaard H. Benefit of combination therapy in epilepsy: a review of preclinical evidence with levetiracetam. Epilepsia 2009, 50:387-397.
12. Lallement G., Pernot-Marino I., Foquin-Tarricone A., Baubichon D., Piras A., Blanchet G., Carpentier P. Antiepileptic effects of NBQX against soman-induced seizures. Neuroreport 1994, 5:425-428.
13. Lallement G., Baubichon D., Clarençon D., Gallonier M., Peoc'h M., Carpentier P. Review of the value of gacyclidine (GK-11) as adjuvant medication to conventional treatments of organophosphate poisoning: primate experiments mimicking various scenarios of military of terrorist attack by soman. Neurotoxicology 1999, 20:675-684.
14. Ligtenstein D.A., Kossen S.P. Kinetic profile in blood and brain of the cholinesterase reactivity oxime HI-6 after intravenous administration to the rat. Toxicol Appl Pharamacol 1983, 71:177-183.
15. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., Fuks B. The synaptic vesicle protein SV2A is the biding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004, 101:9861-9866.
16. McDonough J.H., Shih T.-M. Pharmacological modulation of soman-induced seizures. Neurosci Biobehav Rev 1993, 17:203-215.
17. McDonough J.H., Shih T.-M. A study of the N-methyl-d-aspartate antagonistic properties of anticholinergic drugs. Pharmacol Biochem Behav 1995, 51:249-253.
18. McDonough J.H., Shih T.-M. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci Biobehav Rev 1997, 21:559-579.
19. McDonough J.H., Dochterman W., Smith C.D., Shih T.-M. Protection against nerve agent-induced neuropathology, but not cardiac pathology, is associated with the anticonvulsant action of drug treatment. Neurotoxicology 1995, 15:123-132.
20. McDonough J.H., Clark T., Slone T.W., Zoeffel D., Brown K., Kim S., Smith C.D. Neural lesions in the rat and their relationship to EEG delta activity following seizures induced by the nerve agent soman. Neurotoxicology 1998, 19:381-392.
21. McDonough J., Van Shura K., Lyman M., Eisner C., Mazza A., Kan R., Shih T.-M. Adjuncts for the delayed treatment of nerve agent-induced status epilepticus seizures. Proceedings of Bioscience Review, U S Army Medical Research 2010.
22. Myhrer T. Identification of neuronal target areas for nerve agents and specification of receptors for pharmacological treatment. Neurotoxicology 2010, 31:629-638.
23. Myhrer T., Skymoen L.R., Aas P. Pharmacological agents, hippocampal EEG, and anticonvulsant effects on soman-induced seizures in rats. Neurotoxicology 2003, 24:357-367.
24. Myhrer T., Nguyen N.H.T., Andersen J.M., Aas P. Protection against soman-induced seizures: relationship among doses of prophylactics, soman, and adjuncts. Toxicol Appl Pharmacol 2004, 19:327-336.
25. Myhrer T., Nguyen N.H.T., Enger S., Aas P. Anticonvulsant effects of GABAergic modulators microinfused into area tempestas or substantia nigra in rats exposed to soman. Arch Toxicol 2006, 80:502-507.
26. Myhrer T., Enger S., Aas P. Pharmacological therapies against soman-induced seizures in rats 30min following onset and anticonvulsant impact. Eur J Pharmacol 2006, 548:83-89.
27. Myhrer T., Enger S., Aas P. Anticonvulsant effects of damage to structures involved in seizure induction in rats exposed to soman. Neurotoxicology 2007, 28:819-828.
28. Myhrer T., Enger S., Aas P. Anticonvulsant impact of lesions in the ventrolateral forebrain of rats challenged with soman. Brain Res 2008, 1226:241-247.
29. Myhrer T., Enger S., Aas P. Anticonvulsant efficacy of drugs with cholinergic and/or glutamatergic antagonism microinfused into area tempestas of rats exposed to soman. Neurochem Res 2008, 33:348-354.
30. Myhrer T., Enger E., Aas P. Anticonvulsant efficacy of pharmacological agents microinfused into medial septum of rats exposed to soman. J Med CBR Defense 2009, 7:1-14.
31. Myhrer T., Enger S., Aas P. Roles of perirhinal and posterior piriform cortices in control and generation of seizures: a microinfusion study in rats exposed to soman. Neurotoxicology 2010, 31:147-153.
32. Myhrer T., Enger S., Aas P. Modulators of metabotropic glutamate receptors microinfused into perirhinal cortex: anticonvulsant effects in rats challenged with soman. Eur J Pharmacol 2010, 636:82-87.
33. Oliveira A.A., Nogueira C.R.A., Nascimento V.S., Aguiar L.M.V., Freitas R.M., Sousa F.C.F., Viana G.S.B., Fonteles M.M.F. Evaluation of levetiracetam effects on pilocarpine-induced seizures: cholinergic muscarinic system involvement. Neurosci Lett 2005, 385:184-188.
34. Øydvin O.K., Tansø R., Aas P. Pre-junctional effects of oximes on [3H]-acetylcholine release in rat hippocampal slices during soman intoxication. Eur J Pharmacol 2005, 516:227-234.
35. Raveh L., Chapman S., Cohen G., Alkalay D., Gilat E., Rabinovitz I., Weissman B.A. The involvement of NMDA receptor complex in the protective effect of anticholinergic drugs against soman poisoning. Neurotoxicology 1999, 20:551-560.
36. Raveh L., Weissman B.A., Cohen G., Alkalay D., Rabinovitz I., Sonego H., Brandeis R. Caramiphen and scopolamine prevent soman-induced brain damage and cognitive dysfunction. Neurotoxicology 2002, 23:7-17.
37. Raveh L., Brandeis R., Gilat E., Cohen G., Alkalay D., Rabinovitz I., Sonego H., Weissman B.A. Anticholinergic and antiglutamatergic agents protect against soman-induced brain damage and cognitive dysfunction. Toxicol Sci 2003, 75:108-116.
38. Reynolds I.J., Miller R.J. [3H]MK-801 binding to the N-methyl-d-aspartate receptor reveals drug interaction with the zinc and magnesium binding sites. J Pharmacol Exp Ther 1988, 24:1025-1031.
39. Schmued L.C., Albertson C., Slikker W. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res 1997, 751:37-46.
40. Schmued L.C., Hopkins K.J., Fluoro-Jade B. A high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 2000, 874:123-130.
41. Scremin O.U., Shih T.-M., Li M.G. Mapping of cortical metabolic activation in soman-induced convulsions in rats. Brain Res Bull 1997, 43:425-434.
42. Shih T.-M., Koviak T.A., Capacio B.R. Anticonvulsants for poisoning by the organophosphorous compound soman: pharmacological mechanisms. Neurosci Biobehav Rev 1991, 15:349-362.
43. Shih T.-M., McDonough J.H., Koplovitz I. Anticonvulsants for soman-induced seizure activity. J Biomed Sci 1999, 6:86-96.
44. Shytle R.D., Penny E., Silver A.A., Goldman J., Sanberg P.R. Mecamylamine (Inversine®): an old antihypertensive with new research directions. J Hum Hypertens 2002, 16:453-457.
45. Sterri S.H., Lyngaas S., Fonnum F. Toxicity of soman after repetitive injection of sublethal doses in rat. Acta Pharmacol Toxicol 1980, 46:1-7.
46. Taylor P. Anticholinesterase agents. The pharmacological basis of therapeutics 2001, 175-191. McGraw-Hill Companies Inc., New York. 10th ed. J.G. Hardman, L.E. Limbird, A.G. Gilman (Eds.).
47. Van Helden H.P.M., Busker R.W., Melchers B.P.C., Bruijnzeel P.L.B. Pharmacological effects of oximes: how relevant are they. Arch Toxicol 1996, 70:779-786.